Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study

Shaobo Shi,a,b,c Yanhong Tang,a,b,c Qiyang Zhao,a,b,c Hong Yan,d Bin Yu,d Qiangsun Zheng,e Yigang Li,f Liangrong Zheng,g Yiqiang Yuan,h Jingquan Zhong,i Jian Xu,j Yanqing Wu,k Jingfeng Wang,l Minglong Chen,m Baopeng Tang,n Wei Li,o Qiang Wu,p Bei Shi,q Shenghua Zhou,q Xingsheng Zhao,q Yuehui Yin,r Zheng Zhang,s Guoqiang Zhong,aa Xuebin Han,ab Fan Liu,ac Ming Wu,ad Lianjun Gao,a He Huang,a,b,c* and Congxin Huang,a,b,c*, (On behalf of the China Atrial Fibrillation Center Project Team)

aDepartment of Cardiology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan 430060, Hubei, China
bHubei Key Laboratory of Cardiology, Wuhan University, Wuhan 430060, China
cHubei Province Key Laboratory of Cardiology, Wuhan University, Wuhan 430060, China
dSchool of Public Health, Wuhan University, Wuhan 430071, China
eThe Second Affiliated Hospital of Xian Jiaotong University, Xian 710004, China
fXinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
gThe First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
hHenan Provincial Chest Hospital, Zhengzhou 450008, China
iQilu Hospital of Shandong University, Jinan 250063, China
jAnhui Provincial Hospital, Hefei 230006, China
kThe Second Affiliated Hospital of Nanjing University, Nanjing 330002, China
lTianjin Chest Hospital, Tianjin 300222, China
mFujian Provincial Hospital, Fuzhou 350013, China
nThe Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
oWest China Hospital of Sichuan University, Chengdu 610044, China
pSun Yat-sen Memorial Hospital, Guangzhou 510120, China
qThe First People’s Hospital of Kunming 650034, China
rJiangsu Province Hospital, Nanjin 210029, China
sThe First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
tThe Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
uGuizhou Provincial People’s Hospital, Guizhou 550002, China
vGuizhou Provincial Hospital, Guiyang 550002, China
wAffiliated Hospital of Zunyi Medical University, Zunyi 563009, China
xThe Second Affiliated Hospital of Central South University, Changsha 430062, China
yInner Mongolia Autonomous Region People’s Hospital, Hohhot 010020, China
zThe Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
{The First Hospital of Lanzhou University, Lanzhou 730013, China
aaThe First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
abShanxi Cardiovascular Hospital, Taiyuan 030024, China
acThe Second Hospital of Hebei Medical University, Shijiazhuang 050004, China
adHaining General Hospital, Haikou 570311, China
aeThe First Affiliated Hospital of Dalian Medical University, Dalian 116051, China
afThe First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
agHaining General Hospital, Haikou 570311, China
ahThe First Affiliated Hospital of Dalian Medical University, Dalian 116051, China
aiThe First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
ajXinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
akThe Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
alThe First Hospital of Lanzhou University, Lanzhou 730013, China
amThe Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
anThe Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
aoAffiliated Hospital of Zunyi Medical University, Zunyi 563009, China
apAffiliated Hospital of Zunyi Medical University, Zunyi 563009, China
aqOuter Mongolia Autonomous Region People’s Hospital, Hohhot 010020, China
arThe Second Hospital of Shandong University, Jinan 250063, China
asThe First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
atThe Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
auGuizhou Provincial People’s Hospital, Guizhou 550002, China
avGuizhou Provincial Hospital, Guiyang 550002, China
bwThe Second Affiliated Hospital of Central South University, Changsha 430062, China
bxThe Second Hospital of Shandong University, Jinan 250063, China
byThe Second Affiliated Hospital of Kunming 650034, China
bzThe First Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China
caThe Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
Atrial fibrillation (AF) is the most common persistent cardiac arrhythmia. This study aimed to estimate its prevalence and explore associated factors in adults aged 18 years or older in China.

Methods Study data were derived from a national sample from July 2020 to September 2021. Participants were recruited using a multistage stratified sampling method from twenty-two provinces, autonomous regions, and municipalities in China. AF was determined based on a history of diagnosed AF or electrocardiogram results.

Abbreviations: AF, atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; CHF, chronic heart failure; CI, confidence interval; DM, diabetes mellitus; ECG, electrocardiogram; HTN, hypertension; OR, odds ratio; SD, standard deviation; TIA, transient ischaemic attack

*Corresponding authors at: Department of Cardiology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuchang District, Wuhan 430060, China.
E-mail addresses: huanghai7977@whu.edu.cn (H. Huang), huangcongxin@vip.163.com (C. Huang).
† These authors contributed to the work equally and should be regarded as co-first authors.

www.thelancet.com Vol 23 Month June, 2022
**Findings** A total of 114,039 respondents were included in the final analysis with a mean age of 55 years (standard deviation 17), 52.1% of whom were women. The crude prevalence of AF was 2.3% (95% confidence interval [CI] 1.7-2.8) and increased with age. The age-standardized AF prevalence was 1.6% (95% CI 1.6-1.7%) overall, and 1.7% (1.6-1.8%) in men, 1.4% (1.3-1.5%) in women, 1.6% (95% CI 1.5-1.7%) in men, women, urban areas, and rural areas, respectively. The prevalence was higher in the central regions (2.5%, 2.3-2.7%) than in the western regions (1.3%, 1.0-2.0%) and eastern regions (1.1%, 1.0-1.2%) in the overall population, either in the gender or residency subgroups. The associated factors for AF included age (per 10 years; odds ratio 1.02; 95% CI 1.01-1.04; p < 0.001), hypertension (1.22; 95% CI 1.12-1.33; p < 0.001), coronary heart disease (1.44; 95% CI 1.28-1.62; p < 0.001), chronic heart failure (3.70; 95% CI 3.22-4.26; p < 0.001), valvular heart disease (2.13; 95% CI 1.72-2.63; p < 0.001), and transient ischaemic attack/stroke (1.22; 95% CI 1.04-1.43; p = 0.013).

**Interpretation** The prevalence of AF was 1.6% in the Chinese adult population and increased with age, with significant geographic variation. Older age, male sex, and cardiovascular disease were potent factors associated with AF. It is crucial to increase the awareness of AF and disseminate standardized treatment in clinical settings to reduce the disease burden.

**Funding** This research was supported the Nature Science Foundation of Hubei province (No: 2017CFB204).

**Copyright** © 2022 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

**Keywords:** Atrial fibrillation; Prevalence; Factor; Adult; China

**Introduction**

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and mortality. AF is estimated to affect 2-4% of the adult population worldwide.1,2 In general, the prevalence of AF is projected to increase with population aging and social industrialization, especially in developing countries, such as China. Over the past two decades, several epidemiological studies on AF prevalence have been conducted in China. In 2004, Zhou et al. reported that the prevalence of AF was 0.61% based on a national epidemiological survey performed in subjects aged 30 to 89 years old in China.1 In southern China, the AF prevalence among participants older than 35 years was 1.46% from 2015 to 2017.4 A cross-sectional study, conducted in northeast China between September 2017 and March 2019, found that the overall AF prevalence was 1.1% in participants older than 40 years.2 However, two national epidemiological studies showed a higher prevalence of AF in populations with similar ages. A nationally representative study found that the standardized prevalence of AF was 2.3% from October 2014 to November 2015,5 and another national community-based survey showed that the weighted AF prevalence was 1.8% between 2014 and 20167, respectively. The inconsistency of the results can be mainly attributed to various participant characteristics, sample sizes, regions, and investigation methods. China has the largest population in the world spread over a vast territory. These studies were either national surveys conducted years to decades ago or based on a small sample restricted to certain areas. Therefore, the results are not representative of the current AF prevalence in the general Chinese population.

Since 2017, the China Cardiovascular Association has promoted Atrial Fibrillation Center programmes, aiming to enhance overall comprehensive management capabilities and reduce the burden of AF in China.8,9 To provide key information needed for the development of national policies to promote the construction of the Atrial Fibrillation Center, we performed a large, national epidemiological study of adults older than 18 years to estimate the prevalence of AF and explore associated factors for AF in China.

**Methods**

**Study design and participants**

The national epidemiology study was part of the real-world study of Chinese atrial fibrillation (RWS-CAF, registration number: ChiCTR19000021250), which was a multicentre, observational, cohort study. Briefly, we used a multistage, stratified cluster sampling procedure to recruit community-dwelling residents aged 18 years or older (Appendix 1). In stage one, we selected twenty-two provinces, autonomous regions, and municipalities or older (Appendix 1). In stage one, we selected twenty-two provinces, autonomous regions, and municipalities that have all established the provincial Atrial Fibrillation Center Alliances (Appendix 2), and divided them into three major geographical regions of China (i.e., Eastern, Central, and Western China). Then, three prefecture-level cities/areas from each provincial region stratified by economic level (based on the median provincial gross domestic product) were randomly selected. The list of
selected prefecture-level cities is summarized in Appendix 3. In stage two, we randomly selected two cities and counties from selected prefecture-level cities based on the level of economic development, which represent samples from urban and rural areas, respectively. In stage three, urban districts and rural townships were randomly selected from every city and county. Finally, participants aged 18 years or older were cluster recruited via telephone and household visits from the selected urban residential and rural village communities, which were randomly selected from urban districts and rural townships. We determined the sample size of each sampling area based on the 2010 China census data.10

We only enrolled permanent residents (those living in their current residence for 6 months or longer) in the selected communities. A total of 329 study sites (193 urban and 136 rural communities) participated in the study. We excluded individuals who were unable to complete the ECG examination due to physical disabilities, pregnancy or breastfeeding. The study protocol was approved by the Institutional Committee on Human Research at Renmin Hospital of Wuhan University (Wuhan, China). Written informed consent was obtained from all study participants. Patients and the public were not involved in the design, conduct, reporting or dissemination of this research. The details of the organization, survey process and quality control are supplemented in Appendix 1.

Data collection and definitions
We collected data on demographic information, lifestyle factors (e.g., smoking, drinking), and medical history using a questionnaire during the face-to-face interviews. Medical history was obtained according to participants’ medical records or self-reports, and information regarding hypertension (HTN), hyperlipidaemia, diabetes mellitus (DM), coronary heart disease (CHD), chronic heart failure (CHF), valvular heart disease, stroke, and transient ischaemic attack (TIA) was obtained. The CHA2DS2-VASC score was calculated from the sum of the risk factors of congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, and sex category (female); weighing each by 1 except for stroke and age ≥75 years, which were weighed by 2.1 If a participant had a medical history of AF, information, such as AF pattern and treatment, was also recorded in detail. Five patterns of AF were distinguished, based on medical records, presentation, duration, and spontaneous termination of AF episodes, in participants previously diagnosed with AF. The definition of diseases was supplemented in the Appendix 1.

Twelve-lead body surface electrocardiogram (ECG) or a single-lead ECG was obtained for all participants in a quiet situation using a recorder from Shinall Technology (http://www.xinluomed.com). The ECG recordings were separately analysed by two well-trained cardiologists; another investigating cardiologist reviewed the results when their analysis results were inconsistent. If there was uncertainty about the presence of AF, the ECGs were adjudicated by a consensus group. Consistent with the recent European Society of Cardiology guidelines,1 AF was defined as a standard 12-lead ECG

Research in context

Evidence before this study
We searched PubMed and the China National Knowledge Infrastructure database for articles published up to September 30, 2021 using the English and Chinese terms “atrial fibrillation”, “prevalence”, “epidemiology”, and “China”. In 2004, the prevalence of AF in China in individuals between the ages of 30 and 85 years was 0.61%, as reported by Zhou. In 2013, Li reported that the AF prevalence was 1.86% in individuals aged 60 years or older in Shanghai City. In 2015, using a medical insurance database of 471,446 individuals in South-west China, Guo reported that the prevalence of incident AF in subjects older than 20 years was 0.2%. In southern China, the prevalence of AF among participants older than 35 years was 1.46% from 2015 to 2017. Du et al. performed another national community-based survey showed the weighted AF prevalence was 1.8% between 2014 and 2016. In 2018, Wang et al. reported that the prevalence of AF was 2.31% in adults older than 40 years from October 2014 to November 2015. However, no nationwide studies of AF prevalence and associated factors in adults older than 18 years in China have been reported.

Added value of this study
Our large, national, cross-sectional study was undertaken in a sample of 114,039 Chinese adults aged 18 years or older from twenty-two provinces, autonomous regions, and municipalities where have all established the provincial Atrial Fibrillation Center Alliances. Clinical criteria or electrocardiogram results were used to diagnose AF. Our results show that the overall prevalence of AF was 1.6% and increased with age, with significant geographical variation. Senior age, men, hypertension, hyperlipidaemia, coronary heart disease, chronic heart failure, valvarul heart disease, and stroke/transient ischaemic attack were identified as major associated factors for AF.

Implications of all the available evidence
Our findings suggest an increase in the prevalence of AF compared with previous studies. Our study calls for new national policies and programs for the prevention and detection of AF. Specifically, raising awareness of diseases, screening for AF using smart tools, and disseminating standardized treatment in high-risk individuals should be public health priorities.
Recording or a single-lead ECG tracing of ≥ 30 s showing heart rhythm with no discernible repeating P waves and irregular RR intervals or a documented medical history of diagnosed AF. We also obtained physical measurements, including height, weight, and blood pressure, following standard protocols.11,12 Body mass index (BMI) was calculated as weight divided by the square of height (kg/m²), and obesity was defined as a BMI ≥ 28 kg/m².13

Statistical analysis
We estimated the prevalence of AF among all participants. All calculations were weighted to represent the general adult population aged 18 years or older in China according to the 2010 population census,9 and were stratified by sampling clusters. Age-standardized rates of AF prevalence were also calculated using data from the 2010 Chinese census.10 Sampling weights at each level were equal to the reciprocal of the relevant sampling probability. Continuous variables are presented as the mean ± standard deviation (SD), and categorical variables are presented as counts and percentages (%). We used all participants for whom the variables of interest were available. We did not impute missing data. Means were compared with Analysis of Variance, and proportions were compared with the Chi-square test. Cochran-Armitage test was used to evaluate the trend of AF prevalence in different age groups. Multivariate logistic regression with stepwise model was performed to estimate the association of the odds of AF with age (per 10 years), sex, residence location, geographical regions (east, central, west), ethnic origin, marital status, education level, obesity, current smoker, current drinker, and medical history (including HTN, DM, hyperlipidaemia, CHD, CHF, valvular heart disease, and TIA/stroke). Four models were built to assess factors applicable among the total population, and three geographical regions (east, central, west), ethnic origin, marital status, education level, obesity, current smoker, current drinker, and medical history (including HTN, DM, hyperlipidaemia, CHD, CHF, valvular heart disease, and TIA/stroke). Four models were built to assess factors applicable among the total population, and three geographical regions. All analyses were performed using SAS 9.4 (SAS Institute, NC, USA) or SPSS V.20.0 software (IBM, West Grove, Pennsylvania, USA), and statistical significance was defined as p < 0.05 with two-tailed testing.

Role of the funding source
The study funder had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript. The corresponding author had full access to the data and the final responsibility to submit for publication.

Results
Between July 2020 and September 2021, a total of 130,541 (61,584 men and 68,957 women) individuals were approached through the survey. A total of 115,810 people (55,723 men and 60,087 women) completed the study. The overall response rate was 88.7% (90.5% men and 87.1% women). Response rates in three geographical regions and twenty-two provincial regions are presented in Appendix 1. After excluding individuals with unreliable ECG tests, 114,039 participants were enrolled in the final analysis (Figure 1). The mean age of the participants was 55 years (SD 17). In total, 59,431 (52.1%) participants were women, and 72,837 (63.9%) resided in urban areas. The characteristics of the study population are presented in Table 1.

Overall, 2.3% (2,604, 95% confidence interval [CI] 1.7-2.8%) of the study population had AF. Among participants with AF, 1,463 (56.2%) cases had a medical history of AF and 1,141 (43.8%) cases of newly diagnosed AF, 101 (3.9%) cases and 2,503 (96.1%) cases of AF were diagnosed with valvular and non-valvular AF, respectively. People with AF were more likely to be men, older, urban residents, married, obese, and have HTN, DM, hyperlipidaemia, CHD, CHF, valvular heart disease, and TIA/stroke, as well as have a lower educational level than those without AF (Table 1). Among participants previously diagnosed with AF, the mean age was 69 years (12), 45.0% were women, 5.9% had valvular AF, and 93.1% had a CHA2DS2-VASc score greater than 1 in participants with non-valvular AF (Appendix 5). 32.1% of patients received anticoagulation therapy, and the anticoagulation rate was higher in urban areas than that in rural areas (390 [36.6%] vs 79 [19.8%]; p < 0.001, Appendix 5). The crude AF prevalence was higher in men than in women (2.6% [2.5-2.7%] vs 2.0% [1.9-2.1%]; p < 0.001), and in urban areas than in rural areas (2.4% [2.2-2.6%] vs 2.0% [1.8-2.2%]; p < 0.001). The prevalence of AF increased with age both in the total population (Appendix 6) and in three geographical regions (Appendix 7), and the overall prevalence increased from 0.4% (46 of 10,750, 0.4-0.7%) at ages of 18-29 years to 5.9% (371/6,239, 5.4-6.5%) at ages of 80 years or older (p < 0.001). AF prevalence also increased with age in both men and women, urban

Figure 1. Flow of participants through the study.
with men, women had a lower age-standardized AF prevalence (women 1.4% [95% CI 1.3-1.5%] vs. men 1.7% [1.6-1.8%]). No significant difference was noted between urban and rural areas (urban areas 1.6% [95% CI 1.5-1.7%] vs. rural areas 1.7% [1.6-1.9%]). The age-standardized AF prevalence varies by geographical region, and the prevalence was highest in the central region (2.5%, 2.3-2.7%) followed by the western (1.5%, 1.0-2.0%) and eastern regions (1.1%, 1.0-1.2%). The central region had also higher age-standardized AF prevalence (women 1.4% [95% CI 1.3-1.5%] vs. men 1.7% [1.6-1.8%]).

After weighing and adjusting using data from the 2010 Chinese census, the age-standardized prevalence of AF was 1.6% (95% CI 1.6-1.7%) overall. Compared with men, women had a lower age-standardized AF prevalence (women 1.4% [95% CI 1.3-1.5%] vs. men 1.7% [1.6-1.8%]). No significant difference was noted between urban and rural areas (urban areas 1.6% [95% CI 1.5-1.7%] vs. rural areas 1.7% [1.6-1.9%]). The age-standardized AF prevalence varies by geographical region, and the prevalence was highest in the central region (2.5%, 2.3-2.7%), followed by the western (1.5%, 1.0-2.0%) and eastern regions (1.1%, 1.0-1.2%). The central region had also higher age-standardized AF prevalence (women 1.4% [95% CI 1.3-1.5%] vs. men 1.7% [1.6-1.8%]). No significant difference was noted between urban and rural areas (urban areas 1.6% [95% CI 1.5-1.7%] vs. rural areas 1.7% [1.6-1.9%]). The age-standardized AF prevalence varies by geographical region, and the prevalence was highest in the central region (2.5%, 2.3-2.7%), followed by the western (1.5%, 1.0-2.0%) and eastern regions (1.1%, 1.0-1.2%).

### Table 1: Demographic characteristics of the study population.

| Residence location | Overall (114039 (100%)) | No AF (111435 (97.7%)) | AF (2604 (2.3%)) | p value |
|-------------------|--------------------------|------------------------|----------------|---------|
| Urban             | 72837 (63.9%)            | 71071 (63.8%)          | 1766 (16.8%)   | <0.001 |
| Rural             | 41202 (36.1%)            | 40364 (36.2%)          | 838 (32.2%)    | <0.001 |
| Geographical region |                          |                        |                |         |
| East              | 60192 (52.8%)            | 58934 (52.9%)          | 1258 (48.3%)   | <0.001 |
| Central           | 36113 (31.7%)            | 35207 (31.6%)          | 906 (34.8%)    | <0.001 |
| West              | 17734 (15.5%)            | 17294 (15.5%)          | 440 (16.9%)    | <0.001 |
| Education attainment |                          |                        |                |         |
| Primary school or less | 67878 (59.5%)          | 66114 (59.3%)          | 1764 (67.7%)   | <0.001 |
| Middle and High school | 24409 (21.4%)         | 23881 (21.4%)          | 528 (20.3%)    | <0.001 |
| College and higher | 21752 (19.1%)            | 21440 (19.3%)          | 312 (12.0%)    | <0.001 |
| Ethnic Group      |                          |                        |                |         |
| Han               | 108848 (95.4%)           | 106359 (95.4%)         | 2489 (95.6%)   | 0.771  |
| Non-Han           | 5191 (4.6%)              | 5076 (4.6%)            | 115 (4.4%)     | <0.001 |
| Marital status    |                          |                        |                |         |
| Married           | 101571 (89.1%)           | 99205 (89.0%)          | 2366 (90.9%)   | 0.003  |
| Widowed, divorced, single, or other | 12468 (10.9%)     | 12230 (11.0%)          | 238 (9.1%)     | <0.001 |
| Current smoker    | 12583 (11.0%)            | 12278 (11.0%)          | 305 (11.7%)    | 0.268  |
| Current drinker   | 9628 (8.4%)              | 9381 (8.4%)            | 247 (9.5%)     | 0.053  |
| Obesity (BMI≥28 kg/m²) | 10969 (9.6%)        | 10676 (9.6%)           | 293 (11.3%)    | 0.004  |
| Medical History   |                          |                        |                |         |
| HTN               | 29859 (26.2%)            | 28824 (25.9%)          | 1035 (39.7%)   | <0.001 |
| DM                | 11151 (9.8%)             | 10688 (9.6%)           | 463 (17.8%)    | <0.001 |
| Hyperlipidaemia   | 11270 (9.9%)             | 10833 (9.7%)           | 437 (16.8%)    | <0.001 |
| CHD               | 8982 (7.9%)              | 8390 (7.5%)            | 592 (22.7%)    | <0.001 |
| CHF               | 2756 (2.4%)              | 2364 (2.1%)            | 392 (15.1%)    | <0.001 |
| Valvular heart disease | 1137 (1.0%)            | 998 (0.9%)             | 139 (5.3%)     | <0.001 |
| TIA/stroke        | 3339 (2.9%)              | 3088 (2.8%)            | 251 (9.6%)     | <0.001 |
prevalence compared with western and eastern regions for both the men and women, urban and rural areas (Figure 3).

In multivariate logistic regression analysis of the total population, AF was significantly associated with older age (per 10 years; odds ratio 1.41 [95% CI 1.38-1.45]; p < 0.001), men (1.34 [1.24-1.45]; p < 0.001), HTN (1.22 [1.12-1.33]; p < 0.001), CHD (1.44 [1.28-1.62]; p < 0.001), CHF (3.70 [3.22-4.26]; p < 0.001), valvular heart disease (2.13 [1.72-2.61]; p < 0.001), and TIA/stroke (1.22 [1.04-1.43]; p = 0.013) after adjusting for residence location, geographical regions, ethnic origin, marital status, education level, obesity, current smoker, current drinker, and hyperlipidaemia (Table 2). Among the eastern region, older age, men, and have a HTN, hyperlipidaemia, CHD, CHF, valvular heart disease, and TIA/stroke remained significantly associated with the prevalence of AF. However, hyperlipidaemia and TIA/stroke were no longer significantly associated factors among the central region. Moreover, non-Han nationality (1.75 [1.25-2.44]; p = 0.001) became a new factor among the western region, but men remained nonsignificant (Table 2).

**Discussion**

To our knowledge, the present large national investigation provided important information on AF in China. First, our results showed that the overall prevalence of AF was 1.6% in Chinese adults. This value is greater than previous estimates and indicates a 146% increase compared with the previous study performed in 2004. Second, the prevalence of AF increases with age, and men had a higher AF prevalence than women, but significant differences were not noted between urban and rural residents. Moreover, the AF prevalence presented an obvious geographic variation, with a greater prevalence in the central region. Third, factors associated with AF included older age, men and previous cardiovascular diseases, with a subtle difference among the three geographical regions. Considering the vast population of China, the burden of AF is heavy. AF remains an important public health problem in China that requires attention.

Since the study reported by Zhou et al. two decades ago, several epidemiological surveys on AF prevalence have been performed in China. However, there has been a lack of national epidemiological studies of AF...
during the past five years. Previous studies have reported inconsistent results due to the differences in study design and participant characteristics. Ten years ago, Li Lihua and colleagues enrolled 3,922 individuals aged 60 years or older and found that the AF prevalence was 1.80% in Shanghai City. Two other studies conducted in Northeast and South China found AF prevalence rates of 1.10% and 1.46% in individuals older than 40 years and 35 years, respectively. However, two national cross-sectional studies conducted at five years ago showed standardized prevalence rate of AF of 2.31% and 1.8%, which were all higher than those in regional surveys. The inconsistent results suggest that many complex factors influence AF prevalence, such as population characteristics, survey methodology, regional medical service capacity and economic level, etc. AF prevalence is positively correlated with advancing age, but data on adults aged younger than 35 years are lacking in China. Guo Yutao et al. in 2015 used a medical insurance database from 2001 to 2012 in Southwest China to identify that the prevalence of incident AF was 0.2% in subjects aged 20 years or older. However, the data were restricted to hospital medical records and did not include on-site investigations. The prevalence of AF may not reflect the true prevalence in adults in China. Our results revealed that the AF prevalence was 1.6% in Chinese adults aged 18 years or older, and increased from 0.4% in the age group of 18 – 29 years to 5.9% in the age group including those 80 years or older. Our data suggest the need to channel more attention to the young population with AF because the prevalence may not be not as low as expected.

Our findings suggest that AF has become more common across China in the past 20 years. Several potential reasons could be account for the substantial increase. First, extended longevity has become a more obvious sociodemographic phenomenon with rapid population aging in China. The acceleration of population aging has exceeded that of many developed countries, and the proportion of adults aged 60 years and older is expected to increase from 12.4% to 28% between 2010 and 2040. Aging populations and subsequent cardiovascular diseases are the primary drivers of AF development and progression. Second, convenient screening tools developed in recent years, such as smart watches and long-term single-lead patches, greatly facilitate the detection and diagnosis of AF. Other self-service devices with intelligent algorithms provide more choices for opportunistic screening of AF, especially in

Figure 3. Age-standardized AF prevalence in three geographical regions. Age-standardized AF prevalence in men (A) and women (B) as well as urban (C) and rural (D) subgroups in three geographical regions.
Table 2: Association of different patient characteristics and atrial fibrillation in multivariate logistic regression models. CHD=coronary heart disease, CHF=chronic heart failure, CI=confidence interval, DM=diabetes mellitus, HTN=hypertension, OR=odds ratio, ref-reference, TIA=transient ischaemic attack.

| Model 1: Among eastern region | OR (95%CI) | p value |
|-------------------------------|-----------|---------|
| Age (per 10 years)            | 1.47 (1.42-1.53) | <0.001 |
| Sex                           |           |         |
| Men                           | 1.36 (1.21-1.52) | <0.001 |
| Women                         | 1 (ref)   |         |
| HTN                           |           |         |
| Yes                           | 1.22 (1.08-1.39) | 0.002  |
| No                            | 1 (ref)   |         |
| Hyperlipidaemia                |           |         |
| Yes                           | 1.35 (1.15-1.59) | 0.001  |
| No                            | 1 (ref)   |         |
| CHD                           |           |         |
| Yes                           | 1.35 (1.12-1.62) | 0.002  |
| No                            | 1 (ref)   |         |
| CHF                           |           |         |
| Yes                           | 3.70 (2.92-4.69) | <0.001 |
| No                            | 1 (ref)   |         |
| TIA/stroke                     |           |         |
| Yes                           | 1.81 (1.31-2.52) | <0.001 |
| No                            | 1 (ref)   |         |
| Model 2: Among central region | OR (95%CI) | p value |
| Age (per 10 years)            | 1.38 (1.31-1.44) | <0.001 |
| Sex                           |           |         |
| Men                           | 1.40 (1.22-1.60) | <0.001 |
| Women                         | 1 (ref)   |         |
| HTN                           |           |         |
| Yes                           | 1.22 (1.06-1.42) | 0.007  |
| No                            | 1 (ref)   |         |
| CHD                           |           |         |
| Yes                           | 1.79 (1.48-2.15) | <0.001 |
| No                            | 1 (ref)   |         |
| CHF                           |           |         |
| Yes                           | 3.03 (2.41-3.82) | <0.001 |
| No                            | 1 (ref)   |         |
| Valvular heart disease        |           |         |
| Yes                           | 1.84 (1.30-2.59) | <0.001 |
| No                            | 1 (ref)   |         |
| Model 3: Among western region | OR (95%CI) | p value |
| Age (per 10 years)            | 1.38 (1.28-1.49) | <0.001 |
| Ethnic origin                 |           |         |
| Non-Han                       | 1.75 (1.25-2.44) | 0.001  |
| Han                           | 1 (ref)   |         |
| Hyperlipidaemia                |           |         |
| Yes                           | 1.60 (1.26-2.02) | <0.001 |
| No                            | 1 (ref)   |         |
| CHD                           |           |         |
| Yes                           | 1.34 (1.03-1.73) | 0.030  |
| No                            | 1 (ref)   |         |
| CHF                           |           |         |
| Yes                           | 4.54 (3.45-5.99) | <0.001 |

Table 2 (Continued)

patients with paroxysmal and asymptomatic AF. Third, benefiting from the rapid growth of the economy, the country’s medical insurance payment ability, disease management capability of disease and residents’ health awareness have all been substantially improved in China. As a result, the frequency of medical treatment for the general population and the diagnosis rate of AF have gradually increased. This condition subsequently puts a large number of populations at risk of cardioembolic stroke and systemic embolization. However, the anticoagulation therapy has improved substantially compared with a previous study, despite exist the urban-rural disparity, which may be attributed to the construction of the Atrial Fibrillation Center.

Our results found that AF was more frequent in men than in women. Theoretically, oestrogen has a protective effect on the cardiovascular system, which is related to the low prevalence of cardiovascular disease in premenopausal women. In women, a lower risk factor burden of cardiovascular disease and frequent primary prevention strategies, including adoption of healthy

Table 2: Association of different patient characteristics and atrial fibrillation in multivariate logistic regression models. CHD=coronary heart disease, CHF=chronic heart failure, CI=confidence interval, DM=diabetes mellitus, HTN=hypertension, OR=odds ratio, ref-reference, TIA=transient ischaemic attack.
lifestyle behaviours and use of proven medicines, collectively play a protective role to reduce the risk of AF.\textsuperscript{25,26} It should be emphasized that the prevalence of AF was similar between urban areas and rural areas, but showed a large difference among geographical regions. Similar to the geographic variability in other cardiovascular diseases, AF has increased sharply in rural areas as well as urban areas in recent decades. However, its diagnosis rate is closely related to the local economic level, medical service capacity and health awareness, which exhibit considerable geographical disparity.\textsuperscript{27–30} In general, the Eastern China has the highest levels of economic hygiene and the greatest proportion of young adults, which contributes to the lowest prevalence of AF. Unlike the central and eastern regions, non-Han ethnicity became a significant factor associated with AF, while male gender was no longer significant in the western region. This finding suggests that a fundamental structural change is needed to address AF in China. Improvement in adherence to treatment is as important as education and screening. These issues include educating patients, training physicians, and improving medical insurance coverage.

Compared with other Asian countries, China appears to have a higher prevalence of AF. For example, a previous study conducted in 2006 found the estimated overall prevalence of AF in Japanese adults aged greater than 40 years was 1.6\%.\textsuperscript{31} Yonezawa Y reported a 0.92\% of AF prevalence rate in Japanese adults aged 20 years or older from April 2013 to March 2014, with a rate four times higher in men (1.46\%) than in women (0.37\%).\textsuperscript{32} In South Korea, the prevalence of AF in the total adult population was observed to be 0.67\% in 2015.\textsuperscript{33} The estimated AF prevalence was 2.8\% for age ≥ 65 years in Thailand,\textsuperscript{34} and 1.5\% for age ≥ 55 years in Singapore.\textsuperscript{35} Nonetheless, our studies found several common associated factors for AF, such as older age, men, cardiac disease, and TIA/stroke. In addition to differences in population characteristics and survey methods, the lower level of the national health economy could be an important factor that causes a higher AF prevalence in China than those in other Asian countries.

The present study had several potential limitations. First, the major limitation is that self-report questionnaires and medical history may introduce inevitable errors, and potentially lead to bias in the estimation of the prevalence and associated factors. Second, although the included sample was corrected in the final analysis, population migration and exclusion criteria exist in the survey inevitably introduce selection bias. Third, considering the operability and the consistency of the diagnostic criteria, we still used traditional ECG as a screening tool for AF and did not include mobile devices with smart or long recording durations. This study design mainly underestimates the prevalence of paroxysmal AF. Fourth, AF is a heterogeneous disease, and many pathogenic factors could lead to AF. Thus, it is difficult to determine all potential risk factors or predictors, and the interpretation of relevant results might be inconclusive. Finally, as the 2020 population census has not been fully released and is not available, therefore the AF prevalence was weighted according to the 2010 population census. In general, the Chinese population structure presents an aging trend, so it would inevitably affect and lead to AF underestimation the estimates in the current study.

In conclusion, our data indicate that AF is currently more prevalent in the adult population than previously reported in China, and old age, men, and cardiovascular disease are major associated factors for AF. These results suggest a serious situation in terms of prevention and control of AF in China. Strengthening screening and education programs supplemented by protocols and policies that improve adherence to treatment are key issues, that urgently need to be solved to reduce AF burden in China.

**Contributors**

Congxin Huang, He Huang, and Shaobo Shi had the idea for and designed the study. Shaobo Shi, Yanhong Tang, and Qingyan Zhao led the data collection. Yanhong Tang, Quansun Zheng, Yiqiang Li, Liangrong Zheng, Yiqiang Yuan, Jingquan Zhong, Jian Xu, Yanqing Wu, Jing Xu, Lin Chen, Shufeng Li, Jian Jiang, Jingfeng Wang, Jie Fan, Minglong Chen, Baopeng Tang, Wei Li, Qiang Wu, Bei Shi, Shenghua Zhou, Xingsheng Zhao, Yuehui Yin, Zheng Zhang, Guoqiang Zhong, Xuebin Han, Fan Liu, Ming Wu, and Lianjun Gao organized on-site investigation projects in various province. Shaobo Shi, Bo Yang, and Qingyan Zhao did the statistical analysis supported by Hong Yan, and Bin Yu. Shaobo Shi, Qingyan Zhao and Yanhong Tang wrote the draft report. All authors contributed to acquisition, analysis, or interpretation of data. All authors, revised the report and approved the final version before submission.

**Data sharing**

Article components including study protocol, statistical analysis approach, and de-identified data will be available for investigators following approval from the Institutional Review Board of Renmin Hospital of Wuhan University (Wuhan, China). Petitions can be sent to the corresponding author.

Editor note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

**Declaration of interests**

All authors declare no competing interests.
Acknowledgments
We thank Junbo Ge, Yong Huo and other consultants for their instructions and contributions through the whole process of study; Shinall Technology for providing database network and screening equipment. We acknowledge the support provided by all partnership, including The Second Affiliated Hospital of Xi’an Jiao tong University; Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine; The First Affiliated Hospital; Zhejiang University School of Medicine; Henan Provincial Chest Hospital; Qilu Hospital of Shandong University; Anhui Provincial Hospital; The Second Affiliated Hospital of Nanchang University; Tianjin Chest Hospital; Fujian Provincial Hospital; The Second Affiliated Hospital of Harbin Medical University; West China Hospital of Sichuan University; Sun Yat-sen Memorial Hospital; The Second People’s Hospi tal of Yunnan Province; Jiangsu Province Hospital; The First Affiliated Hospital of Xi’an Jiaotong Medical University; The Affiliated Hospital of Guizhou Medical University; Guizhou Provincial People’s Hospital; Affiliated Hospi tal of Zunyi Medical University; The Second Xiangya Hospital of Central South University; Inner Mongolia Autonomous Region People’s Hospital; The Second Affiliated Hospital of Chongqing Medical University; The First Hospital of Lanzhou University; The First Affiliated Hospital of Guangxi Medical University; Shanzhi Cardiovascular Hospital; The Second Hospital of Hebei Medical University; Hainan General Hospital; The First Affiliated Hospital of Dalian Medical University. We thank all provincial and regional officers and research staff in China for their collection of data.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.lanwpc.2022.100439.

References
1 Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
2 Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report From the American Heart Associa tion. Circulation. 2019;139:e109–e139.
3 Zhou QZ, Hu DY, Chen J, Zhang RH, Li KB, Zhao XL. An epidemiological survey of atrial fibrillation in China. Zhonghua Nei Ke Za Zhi. 2004;43:491–494. in Chinese.
4 Deng H, Guo P, Zheng M, et al. Epidemiological Characteristics of atrial fibrillation in southern china: results from the Guangzhou heart study. Sci Rep. 2018;8:17842.
5 Xing L, Lin M, Du Z, Jing L, Tian Y, Yan H, et al. Epidemiology of atrial fibrillation in northeast China: a cross-sectional study. 2017– 2019. Heart. 2020;106:590–595.
6 Wang X, Fu Q, Song F, Li W, Yin X, Yue W, et al. Prevalence of atrial fibrillation in different socioeconomic regions of China and its association with stroke: Results from a national stroke screening survey. Int J Cardiol. 2018;279:2–9.
7 Du X, Guo L, Xia S, Da J, Anderson C, Arinta H, et al. Atrial fibrillation prevalence, awareness and management in a nationwide sur vey of adults in China. Heart. 2021;107:535–541.
8 Zhao QY, Shi SR, Huang H, Jiang H, Yang B, Wu G, et al. Contem porary characteristics, management, and outcomes of patients hos pitalized for atrial fibrillation in China: results from the real-world study of Chinese atrial fibrillation registry. Chin Med J (Engl). 2020;153(23):2883–2884.
9 Atrial Fibrillation Center. https://www.china-afc.org/. Accessed 16 November 2021.
10 National Bureau of Statistics of China. 2010 Population census. October 20, 2013. http://www.stats.gov.cn/english/Statisticaldata/CensusData/.
11 Writing Group of 2018 Chinese Guidelines for the Management of Hypertension. Chinese hypertension league, Chinese society of cardiology, Chinese medical doctor association hypertension com mittee. Hypertension branch of China international exchange and promotive association for medical and health care, hypertension branch of Chinese geriatric medical association. 2018 Chinese guidelines for the management of hypertension. Chin J Cardiovasc Med. 2019;24(1):24–56. in Chinese.
12 http://www.ncbi.nlm.nih.gov/201108/2011080110532.pdf.
13 Zhou BF. Cooperative Meta-Analysis Group of the Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults-study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Biomed Environ Sci. 2002;15:83–96.
14 Li LH, Sheng CS, Hu BC, et al. The prevalence, incidence, manage ment and risks of atrial fibrillation in an elderly Chinese population: a prospective study. BMC Cardiovasc Diab. 2015;15:1.
15 Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, inci dence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147:109– 119.
16 Fang EF, Xie C, Schenklen JA, et al. A research agenda for ageing in China in the 21st century (and edition): Focusing on basic and translational research, long-term care, policy and social networks. Ageing Res Rev. 2020;64:101174.
17 Ye P, Jin Y, Er Y, et al. A scoping review of national policies for healthy ageing in Mainland China from 2016 to 2020. Lancet Reg Health West Pac. 2021;13:100068.
18 North BJ, Sinclair DA. The intersection between aging and cardio vascular disease. Circ Res. 2012;110:1107–1108.
19 Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardio vascular disease in China: current features and implications. Nat Rev Cardiol. 2015;12:203–212.
20 Starck L, Sherrer JA, Ko D, Benjamin EJ, Helm RH. Atrial fibrilla tion: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120:1501–1517.
21 Freedman B, Camm J, Calkins H, et al. Screening for atrial fibrilla tion: a report of the AF-SCREEN international collaboration. Circulation. 2017;135:1851–1857.
22 Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consens us document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoameri cana de Estimulación Cardíaca y Electrofisiología (SOLAECE). Europace. 2017;19:1589–1623.
23 Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther. 2012;135:54–70.
24 Murphy E. Estrogen signaling and cardiovascular disease. Circ Res. 2011;109:689–696.
25 Walli-Attaei M, Joseph P, Rosengren A, et al. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low income countries (PURE): a prospective cohort study. Lancet. 2020;396:97–109.
26 Milliet ERC, Peters SAE, Woodward M. Sex differences in risk fac tors for myocardial infarction: cohort study of UK Biobank partici pants. BMJ. 2018;363:k4247.
27 Yan R, Li W, Yin L, Wang Y, Bo J. PURE-China Investigators. Card iovascular Diseases and Risk-Factor Burden in Urban and Rural Communities in High, Middle, and Low-Income Regions of
China: A Large Community-Based Epidemiological Study. J Am Heart Assoc. 2017;6:e004445.

28 National Center for Cardiovascular Diseases, China. Annual Report on Cardiovascular health and Diseases in China 2019. Beijing: Encyclopedia of China Publishing House; 2020.

29 Chen Y, Li L, Zhang Q, Clarke R, Chen J, Guo Y, et al. Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. Int J Cardiol. 2014;172:88–95.

30 Gu D, Gupta A, Muntner P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation. 2005;112:658–665.

31 Iguchi Y, Kimura K, Aoki J, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ J. 2008;72(6):909–913.

32 Yonezawa Y, Horinaka S, Shirakawa C, Kogure Y. Estimated glomerular filtration ratio is a better index than creatinine clearance (Cockcroft-Gault) for predicting the prevalence of atrial fibrillation in the general Japanese population. Hypertens Res. 2018;41(6):451–459.

33 Lee SR, Choi EK, Han K, Cha MJ, Oh S. Prevalence of non-valvular atrial fibrillation based on geographical distribution and socioeconomic status in the Entire Korean population. Korean Circ J. 2018;48(7):622–634.

34 Suwanwela NC, Chutinet A, Autjimanon H, et al. Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study. Int J Cardiol Heart Vasc. 2021;32:100709.

35 Yap KB, Ng TP, Ong HY. Low prevalence of atrial fibrillation in community-dwelling Chinese aged 55 years or older in Singapore: a population-based study. J Electrocardiol. 2008;41(2):94–98.